Trial Profile
A phase III trial of bevacizumab + paclitaxel as a first-line therapy in patients with metastatic breast cancer.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- 18 Nov 2011 New trial record